Home › Trials › NCT06521229

Registry of patients with uncontrolled asthma in Russia

An Ambispective Observational Multicenter Registry of Patients With Uncontrolled Asthma in the Population of the Russian Federation

Observational AstraZeneca · NCT06521229

This study is collecting information from 10,000 adults with uncontrolled asthma in Russia to better understand how the condition affects them and how it is treated.

Quick facts

Study typeObservational
Enrollment9000 (estimated)
SexAll
SponsorAstraZeneca Industry-sponsored
Locations47 sites (Astrakhan and 46 other locations)
Trial IDNCT06521229 on ClinicalTrials.gov

What this trial studies

This observational registry aims to collect comprehensive data on 10,000 adult patients with uncontrolled asthma across 70 outpatient centers in Russia. The study will gather demographic and clinical information to better understand the epidemiology, treatment patterns, and outcomes of uncontrolled asthma in various regions of the country. By analyzing the characteristics of different patient subgroups, the registry seeks to fill the gaps in existing knowledge about asthma management in Russia. The ambispective design will involve two visits for data collection, ensuring a wide coverage of the population.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with a diagnosis of uncontrolled mild to moderate asthma.

Not a fit: Patients with severe asthma or those receiving biological therapy will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights that improve the management and treatment of uncontrolled asthma in Russia.

How similar studies have performed: While there is limited data on similar observational registries in Russia, such approaches have been successful in other countries for understanding asthma epidemiology.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age ≥ 18 years at the time of inclusion;
2. Signed and dated written informed consent in accordance with ICH GCP and local law prior to inclusion in the study;
3. Patients with diagnosis of uncontrolled mild and moderate asthma (according to Global Initiative for Asthma (GINA) score);
4. Patients with the availability of at least 52 weeks of follow-up data (prior to inclusion) in the medical records.

Exclusion Criteria:

1. Patients with severe asthma or/and patients receiving any biological therapy currently or within 52 weeks prior to inclusion;
2. Presence of chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (ILF) currently or in the anamnesis;
3. The participation in any clinical study currently or within 52 weeks prior to inclusion;
4. An acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results.

Where this trial is running

Astrakhan and 46 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Uncontrolled Asthmauncontrolled asthma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.